MedTrace Logo

Genomic and Proteomic Study of Richter Syndrome (CGPSR)

NCT03619512 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2023-03-24

No results posted yet for this study

Summary

Biological study on Richter Syndrome (RS), an agressive lymphoma that arises from Chronic Lymphocytice Leukemia (CLL). RS presents with the same histological aspect as primitive Diffuse Large B-Cell Lymphoma (DLBCL), but is associated with a poor prognosis, due to chemorefractoriness.

This study aims at understanding the biological determinants of chemotherapy resistance in Richter Syndrome.

Conditions

  • Richter Syndrome

Interventions

GENETIC

Whole exome sequencing.

Retrospective biological exploration of the samples, including tumoral DNA exploration.

GENETIC

RNA sequencing

Characterization of tumor transcriptomic profile.

OTHER

Mass spectrometry

Characterization of tumor proteomic profiles.

Sponsors & Collaborators

  • French Innovative Leukemia Organization (FILO)

    collaborator UNKNOWN

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • Julien Broseus, MD, PhD · Central Hospital, Nancy, France

  • Pierre Feugier, MD, PhD · Central Hospital, Nancy, France

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-06
Primary Completion
2023-12-31
Completion
2024-09-05

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03619512 on ClinicalTrials.gov